Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · AGIOS PHARMACEUTICALS, INC. (AGIO)

Agios Q3 revenue rises to $55.4 million from $12.9 million; net loss narrows

Positive Impact 4 of 5 earnings Written later

Agios Pharmaceuticals reported third quarter 2026 net product revenue of $55.4 million, up from $12.9 million a year earlier, and a net loss of $65.0 million, down from $103.4 million. The FDA extended the review deadline for mitapivat in sickle cell disease by three months, to February 1, 2027, which delays a potential launch in that indication.

Key points

  • Q3 2026 total revenue was $55.4 million versus $12.9 million in Q3 2025; U.S. net revenue was $48.7 million.
  • Net loss per share was $(1.09) in Q3 2026 compared with $(1.78) in Q3 2025.
  • The FDA extended the PDUFA goal date for mitapivat in sickle cell disease from November 1, 2026 to February 1, 2027.
  • Cash, cash equivalents and marketable securities were $907.0 million as of September 30, 2026, versus $1.2 billion at December 31, 2025.

The filing

CompanyAGIOS PHARMACEUTICALS, INC. (AGIO)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:33 AM ET
Accession number0001439222-26-000129

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.